Safety and efficacy of switching from Aflibercept to Brolucizumab in patients with neovascular AMD
Not Applicable
Recruiting
- Conditions
- eovascular age-related macular degenereation
- Registration Number
- JPRN-UMIN000042729
- Lead Sponsor
- ational Hospital Organization Tokyo Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of mean injection period after switching to brolucizumab.
- Secondary Outcome Measures
Name Time Method